<DOC>
	<DOC>NCT01668511</DOC>
	<brief_summary>To assess the safety, tolerability and pharmacokinetics of ABT-981 in patients with osteoarthritis of the knee.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee</brief_title>
	<detailed_description>This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study. Thirty-six patients with osteoarthritis of the knee will be selected to participate. Patients will be randomized to receive either ABT-981 or placebo. ABT-981 or placebo will be administered as subcutaneous (under the skin) injections in four dosing groups. Subjects will be administered subcutaneous injections of ABT-981 for up to 8 weeks.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Adult male or female, 40 to 70 years of age, inclusive. History of symptomatic osteoarthritis (OA) of the knee joint for at least 3 months, with typical Osteoarthritis (OA) symptoms Radiographic Osteoarthritis (OA) of KellgrenLawrence (KL) grade 1, 2 or 3 Patients assessment of Osteoarthritis (OA) pain intensity of the study joint is between 40 and 80 on the 0 100 mm VAS scale Other than Osteoarthritis (OA) of the study joint, patient should be in general good health Radiographic OA of KellgrenLawrence grade 4 or chronic opioid user due to severe knee OA History of allergic reaction or significant sensitivity to any constituents of the study drug and acetominophen or history of anaphylactic reaction to any agent Significant trauma or surgery to the study joint within the last year or arthroscopy within 6 months, or, scheduled for major surgery to the study joint Diagnosis of rheumatoid arthritis, other autoimmune disorders or any arthritis other than Osteoarthritis (OA) of the knee. Any uncontrolled medical illness including unstable treatment or therapy.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>